Every year on February 4th, the world comes together to recognize World Cancer Day, a global initiative led by the Union for International Cancer Control (UICC). This day unites individuals, communities, and organizations in the fight against cancer while raising awareness and promoting actions to reduce its global impact. For 2025, the theme “United by Unique” emphasizes the power of individuality in creating a collective force for change.
We sat down with Premier’s leading oncology experts to discuss the deeply personal impact that cancer has on millions of people worldwide. Today, we acknowledge that everyone’s journey with cancer is unique and celebrate the contributions of individuals—from patients and caregivers to researchers and advocates—in building a united front against cancer.
Elaina: As this year’s theme alludes, every individual impacted by cancer has unique perspectives and needs but are all united in a shared ambition to lower the cancer burden and see cancer treated successfully. What role(s) do CRO’s play in supporting these ambitions and how can we become better partners for progress with other stakeholders in the life science industry?

CROs are committed to working with stakeholders across the life science industry to deliver treatments to patients in the most efficient and effective way possible. By the nature of their business, CROs are incentivized to remain on the cutting edge of technology, such as data analytics, artificial intelligence, and digital platforms, offering life science companies ways to streamline clinical trial processes, improve data accuracy, and enhance patient recruitment and retention.
CROs are uniquely positioned to implement patient-focused solutions like wearable sensors, telemedicine, and mobile applications, These advancements help reduce the burden of participating in clinical trials, making them more accessible and inclusive. As a result, trials can better represent diverse populations and lead to more effective treatments.
In addition to their commitment to fostering inclusion, CROs also actively build relationships with community and patient advocacy groups, and work to strengthen relationships with community sites and networks to broaden the pool of patients invited to participate in clinical trials.
Ultimately, CROs want to work with life science companies to improve the clinical trial experience for cancer patients, enhance patient outcomes, and ensure a positive experience for all.
Sandy: With the rise of precision medicine, therapies are becoming more individualized and targeted to meet the unique characteristics of specific tumors and cancer genotypes. What new targeted therapies are you most excited about and where do you see room for growth and future development?

The field of oncology continues to shift toward personalized medicine, with new therapies designed to target the unique molecular and genetic characteristics of specific tumors. RNA-based therapies, such as those that target specific oncogenic drivers or introduce tumor-suppressive factors, are being developed to elicit immune responses against cancer-specific mutations. We’re seeing similar responses with small molecule inhibitors that also specifically target oncogenic mutations.
Further, antibody drug conjugates (ADC) are powerful therapies that can link a cytotoxic payload to a monoclonal antibody, allowing for precise delivery to cancer cells expressing specific targets.
As we look ahead, I’m excited to see continued investigation of liquid biopsies and companion diagnostics to enhance early disease detection, monitor tumor evolution, and guide therapy changes based on the latest molecular profiles. We’re also on the brink of a technological evolution where AI and machine learning will become an integral part in discovering new cancer treatments, further propelling precision oncology to a more sophisticated state.
Ashley: You’ve talked about the importance of engaging clinical sites in the community, not only large hospitals or academic institutions, to support recruitment efforts in oncology clinical trials. How do community sites differ in their ability to meet the unique needs of individual cancer patients?

Community oncology practices often provide more personalized care. Patients typically see the same oncologist and care team throughout their treatment, fostering strong patient-provider relationships. They also reduce the burden of clinical trial participation on patients by offering convenience and accessibility. These sites are usually located closer to patients’ homes, reducing travel time and related expenses, and this proximity can improve adherence to treatment regimens and the quality of the data.
Lastly, because many community oncology practices collaborate with larger hospitals and academic centers, they can leverage shared expertise and resources to provide access to the same great treatment options available at large academic institutions while taking advantage of the smaller community setting to optimize patient outcomes.
Meera: We’ve heard a lot about the need for increasing patient centricity in clinical trials, which emphasizes the importance of treating patients as partners and can involve shared decision-making. In what ways is the oncology clinical trial landscape evolving to become more people-centric, which the World Cancer Day campaign is differentiating from patient-centric as having a broader context within the larger community to address the health of entire populations. And what challenges remain in delivering this approach?

The oncology clinical trials landscape is increasingly adopting people-centric approaches by integrating community engagement, including diverse population representation, addressing social determinants of health, leveraging real-world evidence and decentralized trial designs, and integrating initiatives like Project Optimus, which prioritizes dose optimization and patient safety. These efforts involve caregivers, advocacy groups, and local communities to improve access, awareness, and equity.
Broader initiatives, such as tailoring trial designs to diverse populations and utilizing real-world evidence, reflect a shift toward holistic health improvement. However, challenges remain, including recruiting and retaining diverse participants, addressing systemic disparities in access, building trust within underrepresented communities, and ensuring the scalability of inclusive trial methodologies without compromising scientific rigor.
These obstacles require implementing strategies to improve sustained collaboration across stakeholders to create innovative policy frameworks. I look forward to seeing the strides that the life science industry makes in becoming more people-centric in the years to come.
Moving Forward Together
As we celebrate World Cancer Day 2025, join us in taking a moment to pause and reflect on the unique story of cancer, acknowledging the amazing work of sponsors, advocacy groups, and, most importantly, the patients who dedicate their time to participating in clinical research to advance new life-saving therapies. Together, we can unite to create a powerful future filled with hope, determination, and action.
To hear more perspectives from our oncology experts, book a meeting with them here.
ABOUT PREMIER RESEARCH:
Premier Research, a global clinical research, product development, and consulting company, is dedicated to helping innovators transform life-changing ideas and breakthrough science into new medical treatments. We offer strategic solutions across the entire development lifecycle, from pre-clinical through commercialization, specializing in smart study design and full-service clinical trial management.
Leveraging technology and therapeutic expertise, we deliver clean, conclusive data with a focus on reducing development timelines, securing access to the right patients, and effectively navigating global regulations to ensure submission-ready results.
As an organization that puts patients first, we pride ourselves on helping customers answer the unmet needs of patients across a broad range of medical conditions. Visit premier-research.com.